Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 2/2004

01-02-2004 | Correspondence

Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors’ Reply

Authors: Nancy Thiry, Philippe Beutels, Pierre Van Damme, Eddy Van Doorslaer

Published in: PharmacoEconomics | Issue 2/2004

Login to get access

Excerpt

Hammerschmidt et al. present the results of their own new economic evaluation of varicella vaccination in Germany[1] and question the conclusions of our review of the literature.[2] We have the impression, however, that Hammerschmidt et al. have somewhat misread — and definitely misinterpreted — our review. We still consider our discussion and conclusion to be appropriate. …
Literature
1.
Banz K, Wagenpfeil S, Neiss A, et al. The cost-effectiveness of routine varicella vaccination in Germany. Vaccine 2003; 21: 1256–67CrossRef
2.
Thiry N, Beutels P, Van Damme P, et al. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 2003; 21 (1): 13–38CrossRef
3.
Coudeville L, Paree F, Lebrun T, et al. The value of varicella vaccination in healthy children: cost-benefit analysis of the situation in France. Vaccine 1999; 17 (2): 142–51CrossRef
4.
Galil K, Brown C, Lin F, et al. Hospitalizations for varicella in the United States, 1988 to 1999. Pediatr Infect Dis 2002; 21: 931–4CrossRef
5.
Brisson M, Edmunds WJ, Law B, et al. Epidemiology of varicella zoster virus infection in Canada and the United Kingdom. Epidemiol Infect 2001; 127 (2): 305–14CrossRef
6.
Schmitt III, Booy R, Weil-Oliver C, et al. Child vaccination policies in Europe: a report from the Summits of Independent European Vaccination Experts. Lancet Infect Dis 2003; 3: 103–8CrossRef
7.
Brisson M, Edmunds WJ, Gay NJ. Varicella vaccination: impact of vaccine efficacy on the epidemiology of VZV. J Med Virol 2003; 70: S31–7CrossRef
8.
Halloran ME, Cochi SL, Lieu TA, et al. Theoretical epidemiologic and morbidity effects of routine varicella immunization of preschool children in the United States. Am J Epidemiol 1994; 140: 81–104CrossRef
9.
Edmunds WJ, Brisson M. The effect of vaccination on the epidemiology of varicella zoster virus. Review. J Infect 2002; 44: 221–9
10.
Panagiotopoulos T, Antoniadou I, Valassi-Adam E. Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review. BMJ 1999; 319: 1462–7CrossRef
11.
Seward IF, Jumaan AO, Galil K, et al. Varicella vaccine and shingles. JAMA 2002; 287: 2211–2CrossRef
12.
Brisson M, Gay NJ, Edmunds WJ, et al. Exposure to varicella boosts immunity to herpes-zoster: implications for mass vaccination against chickenpox. Vaccine 2002; 20: 2500–7CrossRef
13.
Thomas SL, Wheeler JG, Hall AJ. Contacts with varicella or with children and protection against herpes zoster in adults: a case-control study. Lancet 2002; 360: 678–82CrossRef
14.
Edmunds WJ, Brisson M, Gay NJ, et al. Varicella vaccination: a double-edge sword? Commun Dis Public Health 2002; 5 (3): 185–6PubMed
15.
Van Damme P, Beutels P. Economic evaluation of vaccination. Pharmacoeconomics 1996; 9 Suppl. 3: S8–S15CrossRef
16.
Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994–2000). Health Econ 2001; 10 (8): 751–74CrossRef
Metadata
Title
Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature. The Authors’ Reply
Authors
Nancy Thiry
Philippe Beutels
Pierre Van Damme
Eddy Van Doorslaer
Publication date
01-02-2004
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 2/2004
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200422020-00006

Other articles of this Issue 2/2004

PharmacoEconomics 2/2004 Go to the issue

Adis Pharmacoeconomic Drug Evaluation

Infliximab

Current Opinion

The Generation Gap

Correspondence

Economic Evaluation of Varicella Vaccination Programmes: A Review of the Literature

Original Research Article

Cost of Stress Urinary Incontinence

Practical Application Article

Health Economic Evaluation of Non-Melanoma Skin Cancer and Actinic Keratosis